<DOC>
	<DOCNO>NCT01465074</DOCNO>
	<brief_summary>Patients schizophrenia display cognitive impairment , reduce attention problem memory . Available medication schizophrenia poorly alleviate memory problem however , research indicate nicotine improves memory . In order memory form , change ( neuroplasticity change ) brain cell communicate . One way induce change use Transcranial Magnetic Stimulation ( TMS ) combine peripheral nerve stimulation Paired Associative Stimulation ( PAS ) paradigm . The investigator laboratory develop novel method measure memory-like brain change use electroencephalography ( EEG ) , TMS PAS . The present study use novel method evaluate effect acute nicotine gum ( 4mg ) placebo ( regular ) gum memory memory-like brain change schizophrenia healthy control . The hypothesis nicotine improve memory facilitate neuroplasticity change prefrontal cortex patient schizophrenia large extent healthy control .</brief_summary>
	<brief_title>Effects Acute Nicotine Treatment Neuroplasticity Memory Patients With Schizophrenia</brief_title>
	<detailed_description>Background : Schizophrenia ( SCZ ) frequently associate mark work memory ( WM ) deficit whose pathophysiology closely related dorsolateral prefrontal cortex ( DLPFC ) -dependent dysfunction [ 1 ] . These deficit predict disease outcome poor response antipsychotic treatment [ 2 ] . Consequently , elucidate physiology DLPFC-dependent WM deficit SCZ key well understanding illness treatment . Patients SCZ display unusually high prevalence smoking high rate smoke cessation failure commonly associate WM deficit [ 3 ] . The central nicotinic acetylcholine receptor ( nAChR ) main target nicotine . Several line evidence strongly suggest nAChR system promise target treat cognitive deficit SCZ . These include follow observation : ( 1 ) expression nAChRs receptor abnormal several brain region , include PFC , post mortem brain patient SCZ , ( 2 ) gene cod nAChR subunit candidate risk gene SCZ nicotine addiction , ( 3 ) smoking abstinence produce deficit WM , correlate blood level nicotine , alleviate smoke re-instatement block nAChR antagonist patient SCZ , healthy control smoker ( e.g. , [ 4 ] ) . However , underlie mechanism nicotine nAChRs affect DLPFC-dependent memory SCZ still unknown . Nicotine-induced increase neural plasticity may represent one mechanism . Neuroplasticity , include long-term potentiation ( LTP ) , propose physiological mechanism memory formation . LTP dependent optimal interaction glutamate ( GLU ) , dopamine ( DA ) γ-Aminobutyric acid ( GABA ) system perturbation system likely explain patient SCZ demonstrate deficit WM neuroplasticity [ 5,6 ] . nAChR present GABA , GLU DA neuron nicotine could potentially improve cognition modulate system . Studies demonstrate acute nicotine administration potentiate neural plasticity motor cortex healthy human subject . One study use Paired Associative Stimulation ( PAS ) , powerful paradigm index LTP motor cortex , assess effect nicotine LTP non-smokers [ 7 ] . The result demonstrate nicotine enhance LTP-like mechanism induce PAS motor cortex [ 7 ] . To date , however , direct measure LTP-like plasticity DLPFC human . To overcome challenge , investigator group develop novel PAS technique combine transcranial magnetic stimulation ( TMS ) electroencephalography ( EEG ) [ 8 ] directly index LTP DLPFC . Conventional method apply PAS involve repetitive delivery two paired stimulation : first electrical peripheral nerve stimulation right median nerve hand 25 m later second TMS pulse deliver contralateral motor cortex ( hence PAS-25 ) . Through repetitive pairing two stimulation , PAS-25 result increase activation output neuron represent direct measure LTP humans [ 9 ] . The investigator lab recently record PAS-LTP DLFPC use novel technique TMS-EEG [ 8 ] . Here , PAS apply DLPFC repetitive delivery : ( 1 ) peripheral nerve stimulation right side , follow 25 m later ; ( 2 ) TMS pulse deliver left DLPFC . PAS-induced potentiation cortical evoke activity measure directly DLPFC represent LTP region interneurons activate cortical stimulation peripheral stimulation , turn , activate DLPFC output neuron contemporaneously increase activity repeat 30 min . Thus , activation somatosensory cortex peripheral nerve stimulation propagate DLPFC arrive simultaneously TMS pulse result LTP . The validity technique rely observation strong correlation TMS induce evoked potential motor DLPFC ( r=0.8-0.85 , p &lt; 0.001 ) [ 8 ] . LTP quantify change DLPFC cortical evoke activity baseline ( pre-PAS ) different time point follow PAS-25 ( post-PAS ) . Preliminary data investigator ongoing study use novel method , demonstrate PAS-25 induces significant LTP DLPFC . For example , healthy control cortical evoke activity DLPFC facilitate 56 % post-PAS ( maximal point facilitation ) patient SCZ cortical evoke activity post-PAS increase 16 % ( Cohen 's d=0.80 ) . This investigator knowledge first time LTP ever demonstrate in-vivo DLPFC human first time LTP deficit DLPFC report patient SCZ . The aim proposal ass whether enhanced WM nicotine mediate potentiation LTP DLPFC . Hypothesis : 1 . Patients SCZ reduce DLPFC LTP impair WM compare healthy control . 2 . Acute nicotine gum challenge attenuate DLPFC LTP WM deficit patient SCZ . 3 . Plasma nicotine level correlate improvement DLPFC LTP . 4 . Reversal DLPFC LTP deficit patient SCZ associate improvement WM . Methods : Subjects : Fourteen healthy non-smokers 14 non-smokers SCZ complete exploratory study . This sample size base previous study use TMS-EEG method demonstrate significant difference cortical inhibition healthy control SCZ patient [ 10 ] , sufficient detect medium effect size ( Cohen´s d=0.72 ; α=0.05 , 1-β=0.80 ) nicotine treatment . Only patient treat stable dose antipsychotic medication ( ≥1 month ) enrol study . This could potentially confound result investigator use healthy non-medicated control comparison . However , within- subject design effort control effect . Study design : The study double-blinded , placebo-controlled , crossover study consist two PAS-25 test session one month apart , follow 7 day post-PAS follow-up test session . Pharmacological treatment : Nicotine ( 4 mg ) match placebo gum administer two test day baseline TMS-EEG recording . Maximum nicotine blood concentration reach 30 min , point blood sample draw assess nicotine level . WM assessment : The N-back task measure ability maintain active information online ( i.e . WM ) dependent DLPFC functioning . Letters present continuous sequence subject ask respond recognize present letter letter appear appear N ( 0 , 1 , 2 3 ) letter back , i.e . `` N-back '' . The N-back administered pre-test training session ( control train effect ) , baseline , 120 minute 1 week post PAS . Paired Associative Stimulation ( PAS ) : The pairing occur 30 min period peripheral nerve stimulation TMS DLPFC deliver 0.1 Hz . To assure DLPFC localization , neuronavigational technique use MRIcro/reg software T1-weight MRI scan use . Quantifying LTP : To assess DLPFC LTP , change cortical evoke activity measure use pre- post-PAS TMS-EEG recording . TMS pulse generate use two Magstim 200 stimulators ( Magstim Company Ltd. , UK ) connect 7 cm figure-of-eight coil via Bistim module . A train 100 pulse ( 0.1 Hz ) administer together EEG recording ; ( 1 ) PAS order ass baseline cortical evoke activity ( 2 ) different time point ( 0 , 15 , 30 , 60,120 min 7 day ) follow PAS-25 . EEG record use DLPFC-corresponding electrode 64-channel Synamps 2 EEG system . Cortical evoked activity define area rectify curve average EEG recording ( 50-275 m post-stimulus ) LTP quantify change cortical evoke activity baseline . Statistics : Within subject comparison carry use repeat measure , mixed-factorial , ANOVAs appropriate . Relationship LTP nicotine level assess use Pearson correlation . P-values set 0.05 multiple comparison Bonferroni correct . Significance : The result study provide important new knowledge mechanism underlie cognitive enhancement strategy SCZ . That , investigator intend decipher complex pharmacological mechanism underlie nicotinic cholinergic enhancement plasticity DLPFC . Such finding also help generate important biomarkers cognitive enhance strategy may measure biologically potentially lead development personalize treatment cognitive deficit debilitate disorder .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>Inclusion criterion : Age 1855 year Nonsmoker past smoker , abstinent least last 1 year , nonsmoking status assess test day saliva cotinine level &lt; 15ng/mL exhalation CO level &lt; 10ppm . Females potential childbearing must negative urine pregnancy test inclusion . Women childbearing potential must use contraceptive trial Acceptable mean contraception hormonal method ( pill , injection , vaginal ring ) , male female condom , abstinence , injectable contraceptive , intrauterine device abstinence . Ability willingness speak English Willingness provide inform consent Adequate hearing visual capacity , correct visual/ hearing aid • Right handedness Patients schizophrenia : Current diagnosis schizophrenia schizoaffective disorder accord DSMIV TR criterion Stable antipsychotic treatment dosage past 4 week prior study entry Clinically stable , i.e . psychotic episode require hospitalization within last 3 month prior study inclusion General Current smoker abstinent smoker less 1 year Past current history drug abuse disorder current elicit drug use , positive urine drug screen ( drug besides benzodiazepine ) two test day Current past history neurological disorder , i.e . meet criteria cognitive disorder secondary neurological medical disorder affect central nervous system ( , traumatic brain injury , stroke , Parkinson ) . Current past history seizures Any metal implant Mini Mental Status Examination score ≤17 Diagnosis bipolar disorder current major depressive episode Electroconvulsive Therapy ( ECT ) within 6 month prior study participation Allergy following : nicotine resin , xylitol , butylhydroxythyolen E 321 , sodium carbonate , corn starch , magnesium oxide , D &amp; C Yellow No 10 , menthol , acesulfam potassium , wax , titan oxide , maltitol , sorbitol , gum base , sucralose , palm oil , mannitol , glycerin , calcium carbonate , gum arabic . Any following ; breast feeding , immediate postmyocardial infarction period , lifethreatening arrhythmia , angina pectoris , active temporomandibular joint disease , oral pharyngeal inflammation , history esophagitis peptic ulcer . Healthy control : Any psychiatric diagnosis except simple phobias adjustment disorder diagnose DSM IV TR Psychotropic medication ( except sedative /hypnotics stable dose least 4 week ) . Sedative /hypnotics stable dose less 4 week A firstdegree relative past present history primary psychotic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>nicotine</keyword>
	<keyword>memory</keyword>
	<keyword>plasticity</keyword>
	<keyword>TMS</keyword>
	<keyword>Paired Associative Stimulation</keyword>
</DOC>